Abstract
This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
